GeoVax Labs (GOVX) Receivables (2024 - 2025)
GeoVax Labs (GOVX) posted quarterly Receivables of $532771.0 for Q2 2025, up 77.19% year-over-year from $300677.0 in Q2 2024, and down 64.42% quarter-over-quarter from $1.5 million in Q1 2025.
GeoVax Labs (GOVX) Receivables (2024 - 2025) Analysis & Trends
GeoVax Labs (GOVX) has reported Receivables for 2 consecutive years, with $532771.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Receivables rose 77.19% year-over-year to $532771.0; the TTM figure through Jun 2025 stood at $532771.0 (up 77.19% YoY), while the FY2024 annual figure was $659409.0, changed N/A from the prior year.
- Receivables fell to $532771.0 in Q2 2025 per GOVX's latest filing, from $1.5 million in the prior quarter.
- Across five years, Receivables topped out at $1.5 million in Q1 2025 and bottomed at $300677.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | GeoVax Labs | 2.89 Mn | -252,732.97 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 532,771.00 |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 659,409.00 |
| Sep 30, 2024 | 547,574.00 |
| Jun 30, 2024 | 300,677.00 |